Horizon Kinetics Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Horizon Kinetics Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$653K	Sell	2,168 -104	-5%	-$31.4K	0.01%	198
2026 Q1	$752K	Sell	2,272 -104	-4%	-$35.4K	0.01%	188
2025 Q4	$945K	Sell	2,376 -104	-4%	-$46K	0.01%	170
2025 Q3	$1.13M	Sell	2,480 -279	-10%	-$114K	0.01%	161
2025 Q2	$900K	Sell	2,759 -121	-4%	-$33.5K	0.01%	188
2025 Q1	$778K	Hold	2,880	–	–	0.01%	199
2024 Q4	$678K	Buy	2,880 +121	+4%	+$31.8K	0.01%	215
2024 Q3	$759K	Sell	2,759 -121	-4%	-$31.5K	0.01%	205
2024 Q2	$700K	Hold	2,880	–	–	0.01%	194
2024 Q1	$430K	Hold	2,880	–	–	0.01%	222
2023 Q4	$551K	Sell	2,880 -120	-4%	-$20.4K	0.01%	208
2023 Q3	$531K	Hold	3,000	–	–	0.01%	208
2023 Q2	$570K	Hold	3,000	–	–	0.01%	209
2023 Q1	$601K	Hold	3,000	–	–	0.01%	201
2022 Q4	$713K	Hold	3,000	–	–	0.01%	183
2022 Q3	$600K	Hold	3,000	–	–	0.01%	194
2022 Q2	$438K	Hold	3,000	–	–	0.01%	231
2022 Q1	$490K	Hold	3,000	–	–	0.01%	236
2021 Q4	$509K	Hold	3,000	–	–	0.01%	245
2021 Q3	$566K	Hold	3,000	–	–	0.01%	230
2021 Q2	$509K	Hold	3,000	–	–	0.01%	240
2021 Q1	$424K	Hold	3,000	–	–	0.01%	248
2020 Q4	$390K	Hold	3,000	–	–	0.01%	260
2020 Q3	$437K	Hold	3,000	–	–	0.02%	254
2020 Q2	$444K	Buy	+3,000	New	+$404K	0.02%	251

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Horizon Kinetics Asset Management's ALNY Position: Q2 2026 in Review

Horizon Kinetics Asset Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 4.6% in Q2 2026, selling an estimated $31.4K and leaving 2,168 shares worth $653K. The position accounts for 0.01% of the portfolio, ranked #198.

Horizon Kinetics Asset Management first reported a position in ALNY in Q2 2020 and has held it in 25 quarters since. The position peaked at $1.13M in Q3 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Horizon Kinetics Asset Management held 2,168 shares of Alnylam Pharmaceuticals worth $653K as of Q2 2026.
Horizon Kinetics Asset Management sold 104 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $31.4K.
Alnylam Pharmaceuticals made up 0.01% of Horizon Kinetics Asset Management's portfolio in Q2 2026, its #198 holding.
Horizon Kinetics Asset Management first reported a position in Alnylam Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
Horizon Kinetics Asset Management's Alnylam Pharmaceuticals position peaked at $1.13M in Q3 2025.
785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Horizon Kinetics Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.